Nasdaq
$8.65▲ 0.12%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $297.2MShares out 34.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 4d agoAfter-hours26.10.21 05:28DEFA14AOther#●●●
Benitec Biopharma Inc.
Benitec Biopharma Inc. (BNTC) will hold its annual stockholder meeting on December 3, 2026. The agenda includes the election of Class I directors, ratification of the independent registered public accounting firm, and an advisory vote on executive compensation.…more
$8.65+0.12%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 4d agoAfter-hours26.10.21 05:25DEF 14AOther
Benitec Biopharma Inc.
Benitec Biopharma Inc. will hold its 2026 Annual Meeting of Stockholders virtually on December 3, 2026, to vote on director elections, the appointment of an independent accounting firm, and executive compensation. As of the record date of October 13, 2026, the company had 34,889,313 shares of common stock outstanding, excluding 14,604,643 shares issuable upon the exercise of pre-funded warrants.…more
$8.65+0.12%vs prev closeView filingShare - 10.5Pre-market26.10.05 21:088-KKey event
Benitec Biopharma Inc.
Benitec Biopharma has agreed to provide additional data to the FDA following a Type C meeting regarding the pivotal study for BB-301. The company remains on track to confirm the final study design in Q1 2027 and initiate the pivotal trial in mid-2027. Additionally, interim clinical results from the ongoing Phase 1b/2a study will be presented at the ESGCT Annual Congress in late October 2026.…more
$8.65+0.12%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.5Pre-market26.10.05 21:06Bullish#●●●#●●●
Benitec Biopharma Faces FDA Data Request for BB-301 Study
The FDA has requested additional data regarding the single-arm pivotal study of BB-301 for oculopharyngeal muscular dystrophy. Benitec Biopharma now expects to finalize the study design by the first quarter of 2027.…more
$8.65+0.12%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.14After-hours26.09.15 05:00
●●●●●●●● ●●●●● ●●●●●●
Benitec Biopharma reported a net loss of $45.5 million for fiscal year 2026, driven by increased research and development expenses. The company continues to advance its lead candidate BB-301, with ongoing regulatory discussions and upcoming clinical data presentations serving as key milestones.…more
$8.65+0.12%vs prev close
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report